Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

ifebemtinib

An orally bioavailable inhibitor of the non-receptor, cytoplasmic tyrosine kinase protein tyrosine kinase 2 (focal adhesion kinase 1; FAK1; FAK: PTK2) with potential antineoplastic activity. Upon oral administration, ifebemtinib targets and inhibits, in an adenosine triphosphate (ATP)-competitive manner, PTK2. This prevents PTK2-mediated downstream signaling and inhibits migration, proliferation, invasion, and survival in PTK2-overexpressing tumor cells. The cytoplasmic tyrosine kinase PTK2, a signal transducer for integrins overexpressed in various tumor cell types, is involved in tumor cell invasion, migration and proliferation.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:FAK1 inhibitor IN10018
protein tyrosine kinase 2 inhibitor BI 853520
protein tyrosine kinase 2 inhibitor IN10018
PTK2 inhibitor IN10018
Code name:BI 853520
BI-853520
BI853520
IN 10018
IN-10018
IN10018
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search